Mydecine Innovations Group (Mydecine Innovations Group) LT-Debt-to-Total-Asset : 1.22 (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Mydecine Innovations Group LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Mydecine Innovations Group's long-term debt to total assests ratio for the quarter that ended in Sep. 2023 was 1.22.

Mydecine Innovations Group's long-term debt to total assets ratio declined from Sep. 2022 (1.29) to Sep. 2023 (1.22). It may suggest that Mydecine Innovations Group is progressively becoming less dependent on debt to grow their business.

Mydecine Innovations Group LT-Debt-to-Total-Asset Historical Data

The historical data trend for Mydecine Innovations Group's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mydecine Innovations Group LT-Debt-to-Total-Asset Chart

Mydecine Innovations Group Annual Data

Trend

Dec13

Aug14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

0.02

0.58

0.68

Mydecine Innovations Group Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															1.29	0.68	2.22	5.05	1.22

Mydecine Innovations Group LT-Debt-to-Total-Asset Calculation

Mydecine Innovations Group's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

LT Debt to Total Assets (A: Dec. 2022 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2022 )	/	Total Assets (A: Dec. 2022 )
	=	3.457	/	5.08
	=

Mydecine Innovations Group's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2023 is calculated as

LT Debt to Total Assets (Q: Sep. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2023 )	/	Total Assets (Q: Sep. 2023 )
	=	4.002	/	3.292
	=

Mydecine Innovations Group (OTCPK:MYCOF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Mydecine Innovations Group LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Mydecine Innovations Group's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Mydecine Innovations Group (Mydecine Innovations Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mydecine Innovations Group Inc (OTCPK:MYCOF) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

MYIG:UK 0NF0:Germany MYCO:Canada

Address

789 West Pender Street, Suite 810, Vancouver, BC, CAN, V6C 1H2

Website

https://www.mydecine.com

Mydecine Innovations Group Inc is a biopharma and life sciences company engaged in the research, drug development, and clinical trials of psilocybin products.